Clearmind Medicine Net Worth
Clearmind Medicine Net Worth Breakdown | CMND |
Clearmind Medicine Net Worth Analysis
Clearmind Medicine's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Clearmind Medicine's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Clearmind Medicine's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Clearmind Medicine's net worth analysis. One common approach is to calculate Clearmind Medicine's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Clearmind Medicine's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Clearmind Medicine's net worth. This approach calculates the present value of Clearmind Medicine's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Clearmind Medicine's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Clearmind Medicine's net worth. This involves comparing Clearmind Medicine's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Clearmind Medicine's net worth relative to its peers.
Enterprise Value |
|
To determine if Clearmind Medicine is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Clearmind Medicine's net worth research are outlined below:
Clearmind Medicine had very high historical volatility over the last 90 days | |
Clearmind Medicine may become a speculative penny stock | |
Clearmind Medicine has a very high chance of going through financial distress in the upcoming years | |
Clearmind Medicine Common currently holds 3.61 M in liabilities. Clearmind Medicine Common has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Clearmind Medicine's use of debt, we should always consider it together with its cash and equity. | |
Net Loss for the year was (6.23 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Clearmind Medicine Common currently holds about 1.65 K in cash with (4.56 M) of positive cash flow from operations. | |
Clearmind Medicine has a frail financial position based on the latest SEC disclosures |
Know Clearmind Medicine's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Clearmind Medicine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Clearmind Medicine Common backward and forwards among themselves. Clearmind Medicine's institutional investor refers to the entity that pools money to purchase Clearmind Medicine's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Gotham Asset Management, Llc | 2024-09-30 | 339 K | Advisorshares Investments, Llc | 2024-09-30 | 170.6 K | Ubs Group Ag | 2024-09-30 | 141.3 K | Cornerstone Wealth Group, Llc | 2024-09-30 | 20 K | Citadel Advisors Llc | 2024-09-30 | 17.7 K | Hrt Financial Llc | 2024-09-30 | 12.8 K | Royal Bank Of Canada | 2024-09-30 | 569 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 0.0 |
Follow Clearmind Medicine's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.09 M.Market Cap |
|
Project Clearmind Medicine's profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (3.24) | (3.41) | |
Return On Capital Employed | (14.07) | (13.37) | |
Return On Assets | (3.18) | (3.34) | |
Return On Equity | (10.08) | (9.58) |
When accessing Clearmind Medicine's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Clearmind Medicine's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Clearmind Medicine's profitability and make more informed investment decisions.
Please note, the presentation of Clearmind Medicine's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Clearmind Medicine's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Clearmind Medicine's management manipulating its earnings.
Evaluate Clearmind Medicine's management efficiency
Clearmind Medicine Common has return on total asset (ROA) of (0.5795) % which means that it has lost $0.5795 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.679) %, meaning that it created substantial loss on money invested by shareholders. Clearmind Medicine's management efficiency ratios could be used to measure how well Clearmind Medicine manages its routine affairs as well as how well it operates its assets and liabilities. As of December 3, 2024, Return On Tangible Assets is expected to decline to -3.41. The current year's Return On Capital Employed is expected to grow to -13.37. At present, Clearmind Medicine's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 224.1 K, whereas Other Current Assets are forecasted to decline to about 106.1 K.Last Reported | Projected for Next Year | ||
Book Value Per Share | 3.18 | 3.02 | |
Tangible Book Value Per Share | 2.80 | 2.66 | |
Enterprise Value Over EBITDA | 0.42 | 0.40 | |
Price Book Value Ratio | 0.49 | 0.51 | |
Enterprise Value Multiple | 0.42 | 0.40 | |
Price Fair Value | 0.49 | 0.51 | |
Enterprise Value | 394.5 K | 414.2 K |
Leadership effectiveness at Clearmind Medicine Common is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Return On Equity (2.68) |
Clearmind Medicine Earnings per Share Projection vs Actual
Clearmind Medicine Corporate Management
BCom BComm | CFO Director | Profile | |
Mylene Touboul | Accounting Manager | Profile | |
Gilad Babchuk | Head Communication | Profile | |
Adi Varon | Controller | Profile | |
Pr Haden | Vice Development | Profile | |
Pr MSW | Vice Development | Profile | |
Adi ZuloffShani | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Return On Assets (0.58) | Return On Equity (2.68) |
The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.